Creative Medical Technology Holdings, Inc. (CELZ) stock

CELZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30

$0.62−0.01 (-2.08%)

Close on Nov 12, 2026Market cap $4.06MP/E –Yield –

Creative Medical Technology statistics

77 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: –
Last ex-dividend date: No dividends
Fundamentals through: Sep 30, 2026
Share price as of: Nov 12, 2026

Valuation ratiosIndustry

Market Cap: $4.06M; $280.48M
Enterprise Value: -$2.75M; $148.62M
PS Ratio: 1354.99; 3.60
PB Ratio: 0.58; 2.05
P/TBV Ratio: 0.61; 2.29

Enterprise valuationIndustry

EV / Sales: -916.70; 2.60

Share statisticsIndustry

Shares Outstanding: 7M; 58M
Shares Change (YoY): 86.0%; 10.9%
Shares Change (QoQ): 17.0%; 0.48%
Float: 6M; 49M
Shares Held by Insiders: 15.9%; 12.1%
Shares Held by Institutions: 5.65%; 56.4%

Short sellingIndustry

Short Interest: 66,165; –
Short Interest Change: -19.4%; -0.76%
Short % of Float: 1.19%; 9.06%
Short % of Shares Outstanding: 1.00%; 6.30%
Days to Cover: 1.00; 5.13

Stock price statisticsIndustry

52-Week High: $4.72; –
52-Week Low: $0.59; –
20-Day Moving Average: $0.68; –
50-Day Moving Average: $0.83; –
200-Day Moving Average: $1.51; –
Average True Range (14): $0.06; –
Price Change (1 Week): 1.77%; 1.51%
Price Change (1 Month): -20.2%; -2.37%
Price Change (3 Months): -49.5%; -21.1%
Price Change (6 Months): -72.5%; -22.8%
Price Change (YTD): -68.5%; -22.6%
Price Change (1 Year): -80.7%; -21.0%
Price Change (3 Years): -85.5%; -24.8%
Price Change (5 Years): -98.7%; -76.9%
Price Change (10 Years): -100.0%; -63.2%
Average Volume (10 Days): 96,932; –
Average Volume (20 Days): 106,053; –
Average Volume (90 Days): 5M; –
Relative Volume: 0.01; 0.80
Relative Strength Index (14): 36.2; 44.7
Volatility (1 Year): 142.1%; 80.2%
Beta (5 Years): 1.56; 1.07

MarginsIndustry

Gross Margin: 66.9%; 53.0%
Operating Margin: -256435.0%; -38.5%
Pretax Margin: -248871.0%; -11.8%
Profit Margin: -249160.0%; -31.7%
EBITDA Margin: -256435.0%; -27.7%

Returns on capitalIndustry

Return on Equity (ROE): -119.2%; -51.3%
Return on Assets (ROA): -113.8%; -40.7%
Return on Invested Capital (ROIC): -3736.6%; -32.9%
Return on Capital Employed (ROCE): -110.1%; -38.1%

Financial positionIndustry

Current Ratio: 23.66; 3.31
Quick Ratio: 23.35; 2.41

GrowthIndustry

Revenue Growth (YoY): -50.0%; 7.26%
Revenue Growth (3Y CAGR): -59.2%; 2.25%
Revenue Growth (5Y CAGR): -48.4%; 6.41%

EfficiencyIndustry

Asset Turnover: 0.00; 0.40
Inventory Turnover: 1.00; 2.73
WACC: 12.7%; 10.0%

Income statement (TTM)Industry

Revenue: $3.00K; $66.69M
Gross Profit: $2.01K; $116.10M
Operating Income: -$7.69M; -$20.99M
Pretax Income: -$7.47M; -$13.23M
Net Income: -$7.47M; -$21.61M
EBITDA: -$7.69M; -$16.85M
EPS (Diluted): -$1.98; -$0.75

Balance sheetIndustry

Cash & Short-Term Investments: $6.85M; $67.18M
Net Cash (Debt): $6.85M; $16.98M
Net Cash Per Share: $1.04; $0.72
Equity (Book Value): $6.95M; $52.68M
Book Value Per Share: $1.05; $1.50
Tangible Book Value: $6.62M; $26.74M
Working Capital: $6.64M; $78.52M

Cash flow (TTM)Industry

Operating Cash Flow: -$6.40M; -$12.27M

Dividends and yieldsIndustry

Earnings Yield: -183.9%; -21.0%
Buyback Yield: -193.6%; -0.73%
Shareholder Yield: -193.6%; 0.00%

Taxes and interestIndustry

Income Tax: $0; $74.00K

Scores and fair valueIndustry

Altman Z-Score: -8.73; 0.26
Piotroski F-Score: 4; 4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.

Period	CELZ	S&P 500	Difference	CELZ per year	S&P 500 per year
1 month	-26.7%	-2.7%	−24.0 pts
3 months	-48.6%	-1.7%	−46.9 pts
Year to date	-68.5%	+11.9%	−80.4 pts
1 year	-79.4%	+12.0%	−91.4 pts
3 years	-85.5%	+78.2%	−163.7 pts	-47.5%	+21.2%
5 years	-98.7%	+73.2%	−171.9 pts	-57.8%	+11.6%
10 years	-100.0%	+309.6%	−409.6 pts	-73.7%	+15.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

0M CELZ shares were sold short on Oct 30, 2026, down 19.4% from the previous report, or 1.19% of the shares available to trade. At recent volumes it would take 1.0 days to buy them back. Over the last 20 sessions, 31.0% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	66,165	-19.4%	110,768	1.0
Oct 15, 2026	82,052	-50.2%	94,563	1.0
Sep 30, 2026	164,782	+95.6%	2,143,151	1.0
Sep 15, 2026	84,256	-69.1%	172,085	1.0
Aug 31, 2026	272,812	-53.3%	1,219,586	1.0
Aug 14, 2026	584,609	+823.5%	38,485,659	1.0
Jul 31, 2026	63,307	-17.0%	168,509	1.0
Jul 15, 2026	76,263	-87.3%	1,095,213	1.0
Jun 30, 2026	602,285	+289.0%	18,970,380	1.0
Jun 15, 2026	154,817	+14.2%	53,112	2.9
May 29, 2026	135,625	+1.4%	48,643	2.8
May 15, 2026	133,733	-5.6%	44,421	3.0

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Creative Medical Technology's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Jun 12, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CELZ.

Compare: CELZ vs BCDA · CELZ vs ALLO · CELZ vs INMB · CELZ vs TCRT · CELZ vs SNTI

Company	Revenue	Growth
CELZ	$3.00K	-50.0%
TCRT	$3.00K	-50.0%
BCDA	–	–
ALLO	–	–
INMB	–	–
SNTI	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Held by institutions: 5.7%
Auditor: Haynie
SEC CIK: 1187953

Advertisement
300 × 250

See a number that looks wrong?